{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:37:14Z","timestamp":1792787834768,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":82,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Basic Research Program of Jiangsu Province","award":["BK20250226"],"award-info":[{"award-number":["BK20250226"]}]},{"name":"the Key Research Project of Jiangsu Provincial Health Commission","award":["ZDB2020021"],"award-info":[{"award-number":["ZDB2020021"]}],"id":[{"id":"https:\/\/ror.org\/03eqskn19","id-type":"ROR","asserted-by":"crossref"}]},{"name":"the Social Development Project of Jiangsu Science and Technology Plan","award":["Nos. BE2023656 and BE2017602"],"award-info":[{"award-number":["Nos. BE2023656 and BE2017602"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-16352-0","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T23:46:37Z","timestamp":1782949597000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Human single domain antibody-based CAR-T cells targeting BAFF-R demonstrate promising preclinical activity in B-cell malignancies"],"prefix":"10.1186","volume":"26","author":[{"given":"Cuiling","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sungui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaoe","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoyang","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqing","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taochao","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"key":"16352_CR1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3202","author":"A Barraclough","year":"2023","unstructured":"Barraclough A, Hawkes E, Sehn LH, Smith SM. Diffuse large B-cell lymphoma. Hematol Oncol. 2023. https:\/\/doi.org\/10.1002\/hon.3202.","journal-title":"Hematol Oncol"},{"issue":"5","key":"16352_CR2","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1182\/blood.2021013326","volume":"139","author":"TA Eyre","year":"2022","unstructured":"Eyre TA, Cheah CY, Wang ML. Therapeutic options for relapsed\/refractory mantle cell lymphoma. Blood. 2022;139(5):666\u201377. https:\/\/doi.org\/10.1182\/blood.2021013326.","journal-title":"Blood"},{"issue":"4","key":"16352_CR3","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1002\/ajh.26853","volume":"98","author":"I Aldoss","year":"2023","unstructured":"Aldoss I, Shah BD, Park JH, Muffly L, Logan AC, Brown P, et al. Sequencing antigen-targeting antibodies and cellular therapies in adults with relapsed\/refractory B-cell acute lymphoblastic leukemia. Am J Hematol. 2023;98(4):666\u201380. https:\/\/doi.org\/10.1002\/ajh.26853.","journal-title":"Am J Hematol"},{"issue":"1","key":"16352_CR4","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s11899-021-00615-7","volume":"16","author":"T Al-Juhaishi","year":"2021","unstructured":"Al-Juhaishi T, Ahmed S. Selecting the Optimal CAR-T for the Treatment of B-Cell Malignancies. Curr Hematol Malig Rep. 2021;16(1):32\u20139. https:\/\/doi.org\/10.1007\/s11899-021-00615-7.","journal-title":"Curr Hematol Malig Rep"},{"issue":"1","key":"16352_CR5","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/s13045-022-01379-0","volume":"15","author":"BD Shah","year":"2022","unstructured":"Shah BD, Ghobadi A, Oluwole OO, Worel N, McGuirk JP, Holte H, et al. Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study. J Hematol Oncol. 2022;15(1):170. https:\/\/doi.org\/10.1186\/s13045-022-01379-0.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"16352_CR6","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial. Lancet Oncol. 2019;20(1):31\u201342. https:\/\/doi.org\/10.1016\/S1470-2045(18)30864-7.","journal-title":"Lancet Oncol"},{"issue":"10","key":"16352_CR7","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","volume":"22","author":"SJ Schuster","year":"2021","unstructured":"Schuster SJ, Tam CS, Borchmann P, Worel N, McGuirk JP, Holte H, et al. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021;22(10):1403\u201315. https:\/\/doi.org\/10.1016\/S1470-2045(21)00375-2.","journal-title":"Lancet Oncol"},{"issue":"10254","key":"16352_CR8","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839\u201352. https:\/\/doi.org\/10.1016\/S0140-6736(20)31366-0.","journal-title":"Lancet"},{"issue":"22","key":"16352_CR9","doi-asserted-by":"publisher","first-page":"5607","DOI":"10.1182\/bloodadvances.2020003001","volume":"4","author":"L Vercellino","year":"2020","unstructured":"Vercellino L, Di Blasi R, Kanoun S, Tessoulin B, Rossi C, D\u2019Aveni-Piney M, et al. Predictive factors of early progression after CAR T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma. Blood Adv. 2020;4(22):5607\u201315. https:\/\/doi.org\/10.1182\/bloodadvances.2020003001.","journal-title":"Blood Adv"},{"key":"16352_CR10","doi-asserted-by":"publisher","first-page":"101095","DOI":"10.1016\/j.blre.2023.101095","volume":"60","author":"Y Martin","year":"2023","unstructured":"Martin Y, Franz JK, Agha ME, Lazarus HM. Failure of CAR-T cell therapy in relapsed and refractory large cell lymphoma and multiple myeloma: An urgent unmet need. Blood Rev. 2023;60:101095. https:\/\/doi.org\/10.1016\/j.blre.2023.101095.","journal-title":"Blood Rev"},{"issue":"19","key":"16352_CR11","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1182\/blood.2020010462","volume":"137","author":"P Strati","year":"2021","unstructured":"Strati P, Neelapu SS. CAR-T failure: beyond antigen loss and T cells. Blood. 2021;137(19):2567\u20138. https:\/\/doi.org\/10.1182\/blood.2020010462.","journal-title":"Blood"},{"issue":"5","key":"16352_CR12","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1053\/j.seminhematol.2023.11.007","volume":"60","author":"H Kinoshita","year":"2023","unstructured":"Kinoshita H, Bollard CM, Toner K. CD19 CAR-T cell therapy for relapsed or refractory diffuse large B cell lymphoma: Why does it fail? Semin Hematol. 2023;60(5):329\u201337. https:\/\/doi.org\/10.1053\/j.seminhematol.2023.11.007.","journal-title":"Semin Hematol"},{"issue":"3","key":"16352_CR13","doi-asserted-by":"publisher","first-page":"81","DOI":"10.56875\/2589-0646.1026","volume":"15","author":"YM Vanegas","year":"2022","unstructured":"Vanegas YM, Mohty R, Gadd ME, Luo Y, Aljurf M, Qin H, et al. CAR-T cell Therapies for B-cell Lymphoid Malignancies: Identifying Targets Beyond CD19. Hematol Oncol Stem Cell Ther. 2022;15(3):81\u201393. https:\/\/doi.org\/10.56875\/2589-0646.1026.","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"16352_CR14","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.3389\/fimmu.2018.02285","volume":"9","author":"CR Smulski","year":"2018","unstructured":"Smulski CR, Eibel H. BAFF and BAFF-Receptor in B Cell Selection and Survival. Front Immunol. 2018;9:2285. https:\/\/doi.org\/10.3389\/fimmu.2018.02285.","journal-title":"Front Immunol"},{"issue":"6","key":"16352_CR15","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1182\/bloodadvances.2022008560","volume":"7","author":"Z Dong","year":"2023","unstructured":"Dong Z, Song JY, Thieme E, Anderson A, Oh E, Cheng WA, Kuang BZ, Lee V, Zhang T, Wang Z, et al. Generation of a humanized afucosylated BAFF-R antibody with broad activity against human B-cell malignancies. Blood Adv. 2023;7(6):918\u201332. https:\/\/doi.org\/10.1182\/bloodadvances.2022008560.","journal-title":"Blood Adv"},{"issue":"10","key":"16352_CR16","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1016\/j.humpath.2005.08.005","volume":"36","author":"SJ Rodig","year":"2005","unstructured":"Rodig SJ, Shahsafaei A, Li B, Mackay CR, Dorfman DM. BAFF-R, the major B cell-activating factor receptor, is expressed on most mature B cells and B-cell lymphoproliferative disorders. Hum Pathol. 2005;36(10):1113\u20139. https:\/\/doi.org\/10.1016\/j.humpath.2005.08.005.","journal-title":"Hum Pathol"},{"issue":"8","key":"16352_CR17","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1182\/blood-2004-02-0762","volume":"104","author":"AJ Novak","year":"2004","unstructured":"Novak AJ, Grote DM, Stenson M, Ziesmer SC, Witzig TE, Habermann TM, et al. Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome. Blood. 2004;104(8):2247\u201353. https:\/\/doi.org\/10.1182\/blood-2004-02-0762.","journal-title":"Blood"},{"issue":"1","key":"16352_CR18","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s00428-005-1275-6","volume":"447","author":"N Nakamura","year":"2005","unstructured":"Nakamura N, Hase H, Sakurai D, Yoshida S, Abe M, Tsukada N, et al. Expression of BAFF-R (BR 3) in normal and neoplastic lymphoid tissues characterized with a newly developed monoclonal antibody. Virchows Arch. 2005;447(1):53\u201360. https:\/\/doi.org\/10.1007\/s00428-005-1275-6.","journal-title":"Virchows Arch"},{"issue":"Supplement 1","key":"16352_CR19","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1182\/blood-2025-268","volume":"146","author":"E Budde","year":"2025","unstructured":"Budde E, Del Real M, Baird J, Chen L, Song J, Wang X, Thiruvengadam S, Hu M, Macias A, Marcucci E, et al. BAFFR-CAR T cells (PMB-CT01) demonstrate durable responses and manageable toxicities in relapsed\/refractory B-cell lymphomas with prior CD19-directed therapy failure or CD19-negative disease. Blood. 2025;146(Supplement 1):268\u2013268. https:\/\/doi.org\/10.1182\/blood-2025-268.","journal-title":"Blood"},{"key":"16352_CR20","doi-asserted-by":"publisher","unstructured":"Qin H, Dong Z, Wang X, Cheng WA, Wen F, Xue W, et al. CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies. Sci Transl Med. 2019;11(511). https:\/\/doi.org\/10.1126\/scitranslmed.aaw9414.","DOI":"10.1126\/scitranslmed.aaw9414"},{"issue":"12","key":"16352_CR21","doi-asserted-by":"publisher","first-page":"4031","DOI":"10.1007\/s00262-023-03537-w","volume":"72","author":"Y Luo","year":"2023","unstructured":"Luo Y, Qie Y, Gadd ME, Manna A, Rivera-Valentin R, To T, et al. Translational development of a novel BAFF-R CAR-T therapy targeting B-cell lymphoid malignancies. Cancer Immunol Immunother. 2023;72(12):4031\u201347. https:\/\/doi.org\/10.1007\/s00262-023-03537-w.","journal-title":"Cancer Immunol Immunother"},{"key":"16352_CR22","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.addr.2019.04.006","volume":"141","author":"F Rahbarizadeh","year":"2019","unstructured":"Rahbarizadeh F, Ahmadvand D, Moghimi SM. CAR T-cell bioengineering: Single variable domain of heavy chain antibody targeted CARs. Adv Drug Deliv Rev. 2019;141:41\u20136. https:\/\/doi.org\/10.1016\/j.addr.2019.04.006.","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"16352_CR23","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s40364-021-00332-6","volume":"9","author":"Y Asaadi","year":"2021","unstructured":"Asaadi Y, Jouneghani FF, Janani S, Rahbarizadeh F. A comprehensive comparison between camelid nanobodies and single chain variable fragments. Biomark Res. 2021;9(1):87. https:\/\/doi.org\/10.1186\/s40364-021-00332-6.","journal-title":"Biomark Res"},{"issue":"1","key":"16352_CR24","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41467-019-14119-9","volume":"11","author":"N Lam","year":"2020","unstructured":"Lam N, Trinklein ND, Buelow B, Patterson GH, Ojha N, Kochenderfer JN. Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains. Nat Commun. 2020;11(1):283. https:\/\/doi.org\/10.1038\/s41467-019-14119-9.","journal-title":"Nat Commun"},{"issue":"11","key":"16352_CR25","doi-asserted-by":"publisher","first-page":"4262","DOI":"10.1172\/JCI84813","volume":"126","author":"PJ Paszkiewicz","year":"2016","unstructured":"Paszkiewicz PJ, Frassle SP, Srivastava S, Sommermeyer D, Hudecek M, Drexler I, et al. Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia. J Clin Invest. 2016;126(11):4262\u201372. https:\/\/doi.org\/10.1172\/JCI84813.","journal-title":"J Clin Invest"},{"issue":"6","key":"16352_CR26","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1111\/bjh.14899","volume":"182","author":"N Turazzi","year":"2018","unstructured":"Turazzi N, Fazio G, Rossi V, Rolink A, Cazzaniga G, Biondi A, et al. Engineered T cells towards TNFRSF13C (BAFFR): a novel strategy to efficiently target B-cell acute lymphoblastic leukaemia. Br J Haematol. 2018;182(6):939\u201343. https:\/\/doi.org\/10.1111\/bjh.14899.","journal-title":"Br J Haematol"},{"issue":"1","key":"16352_CR27","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1186\/s12935-021-01923-x","volume":"21","author":"G Li","year":"2021","unstructured":"Li G, Zhang Q, Liu Z, Shen H, Zhu Y, Zhou Z, et al. TriBAFF-CAR-T cells eliminate B-cell malignancies with BAFFR-expression and CD19 antigen loss. Cancer Cell Int. 2021;21(1):223. https:\/\/doi.org\/10.1186\/s12935-021-01923-x.","journal-title":"Cancer Cell Int"},{"issue":"1","key":"16352_CR28","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41467-021-27853-w","volume":"13","author":"DP Wong","year":"2022","unstructured":"Wong DP, Roy NK, Zhang K, Anukanth A, Asthana A, Shirkey-Son NJ, et al. A BAFF ligand-based CAR-T cell targeting three receptors and multiple B cell cancers. Nat Commun. 2022;13(1):217. https:\/\/doi.org\/10.1038\/s41467-021-27853-w.","journal-title":"Nat Commun"},{"key":"16352_CR29","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.coi.2021.05.011","volume":"71","author":"E McAllister","year":"2021","unstructured":"McAllister E, Jellusova J. BAFF signaling in B cell metabolism. Curr Opin Immunol. 2021;71:69\u201374. https:\/\/doi.org\/10.1016\/j.coi.2021.05.011.","journal-title":"Curr Opin Immunol"},{"key":"16352_CR30","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.coi.2021.06.014","volume":"71","author":"E Schweighoffer","year":"2021","unstructured":"Schweighoffer E, Tybulewicz VL. BAFF signaling in health and disease. Curr Opin Immunol. 2021;71:124\u201331. https:\/\/doi.org\/10.1016\/j.coi.2021.06.014.","journal-title":"Curr Opin Immunol"},{"issue":"Supplement 1","key":"16352_CR31","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1182\/blood-2025-813","volume":"146","author":"I Aldoss","year":"2025","unstructured":"Aldoss I, Wang X, Chen L, Song J, Sandhu K, Macias A, Sanani N, Barva B, Guan M, Espinosa R, et al. BAFFR-CAR T cells (PMB-CT01) show promising safety and anti-leukemia efficacy in relapsed\/refractory B-cell ALL patients after CD19-targeted therapy failure, including CD19-negative disease. Blood. 2025;146(Supplement 1):813\u2013813. https:\/\/doi.org\/10.1182\/blood-2025-813.","journal-title":"Blood"},{"issue":"1","key":"16352_CR32","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s40259-019-00392-z","volume":"34","author":"I Jovcevska","year":"2020","unstructured":"Jovcevska I, Muyldermans S. The Therapeutic Potential of Nanobodies. BioDrugs. 2020;34(1):11\u201326. https:\/\/doi.org\/10.1007\/s40259-019-00392-z.","journal-title":"BioDrugs"},{"key":"16352_CR33","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.2147\/IJN.S297631","volume":"16","author":"S Sun","year":"2021","unstructured":"Sun S, Ding Z, Yang X, Zhao X, Zhao M, Gao L, et al. Nanobody: A Small Antibody with Big Implications for Tumor Therapeutic Strategy. Int J Nanomed. 2021;16:2337\u201356. https:\/\/doi.org\/10.2147\/IJN.S297631.","journal-title":"Int J Nanomed"},{"key":"16352_CR34","doi-asserted-by":"publisher","unstructured":"Jin BK, Odongo S, Radwanska M, Magez S, Nanobodies. A Review of Generation, Diagnostics and Therapeutics. Int J Mol Sci. 2023;24(6). https:\/\/doi.org\/10.3390\/ijms24065994.","DOI":"10.3390\/ijms24065994"},{"key":"16352_CR35","doi-asserted-by":"publisher","first-page":"101425","DOI":"10.1016\/j.smim.2020.101425","volume":"52","author":"ER Verhaar","year":"2021","unstructured":"Verhaar ER, Woodham AW, Ploegh HL. Nanobodies in cancer. Semin Immunol. 2021;52:101425. https:\/\/doi.org\/10.1016\/j.smim.2020.101425.","journal-title":"Semin Immunol"},{"issue":"1","key":"16352_CR36","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41392-022-00898-z","volume":"7","author":"Z Dai","year":"2022","unstructured":"Dai Z, Mu W, Zhao Y, Cheng J, Lin H, Ouyang K, et al. T cells expressing CD5\/CD7 bispecific chimeric antigen receptors with fully human heavy-chain-only domains mitigate tumor antigen escape. Signal Transduct Target Ther. 2022;7(1):85. https:\/\/doi.org\/10.1038\/s41392-022-00898-z.","journal-title":"Signal Transduct Target Ther"},{"issue":"9","key":"16352_CR37","doi-asserted-by":"publisher","first-page":"2707","DOI":"10.1016\/j.ymthe.2021.07.001","volume":"29","author":"Z Dai","year":"2021","unstructured":"Dai Z, Mu W, Zhao Y, Zhao Y, Jia X, Liu J, et al. The rational development of CD5-targeting biepitopic CARs with fully human heavy-chain-only antigen recognition domains. Mol Ther. 2021;29(9):2707\u201322. https:\/\/doi.org\/10.1016\/j.ymthe.2021.07.001.","journal-title":"Mol Ther"},{"issue":"2","key":"16352_CR38","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.ymthe.2023.12.018","volume":"32","author":"L Mikkilineni","year":"2024","unstructured":"Mikkilineni L, Natrakul DA, Lam N, Manasanch EE, Mann J, Weissler KA, et al. Rapid anti-myeloma activity by T cells expressing an anti-BCMA CAR with a human heavy-chain-only antigen-binding domain. Mol Ther. 2024;32(2):503\u201326. https:\/\/doi.org\/10.1016\/j.ymthe.2023.12.018.","journal-title":"Mol Ther"},{"key":"16352_CR39","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19631","author":"S Wu","year":"2024","unstructured":"Wu S, Luo Q, Li F, Zhang S, Zhang C, Liu J, et al. Development of novel humanized CD19\/BAFFR bicistronic chimeric antigen receptor T cells with potent antitumor activity against B-cell lineage neoplasms. Br J Haematol. 2024. https:\/\/doi.org\/10.1111\/bjh.19631.","journal-title":"Br J Haematol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16352-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16352-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16352-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T12:04:07Z","timestamp":1790078647000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16352-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16352"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16352-0","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,2]]},"assertion":[{"value":"7 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Milestone Biotechnologies (China) provided the PBMCs from healthy donors, which are commercial products. According to Article 32 of the \u201cEthical Review Measures for Life Sciences and Medical Research Involving Humans\u201d issued by the National Science and Technology Ethics Committee, this study is exempt from ethical review. The animal experiments were approved by the Institutional Animal Care and Use Protocol (AP-C210507.45).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1125"}}